AstraZeneca’s Imfinzi (durvalumab) monotherapy and the combination of Imfinzi with remelimumab have failed to improve overall survival (OS) rate in phase III Mystic lung cancer trial.
Seattle Genetics has dosed the d first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).
Merck has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) significantly improved overall survival (OS) rate in the phase 3 Keynote-181 esophageal cancer trial.
AbbVie’s Mavyret (glecaprevir/pibrentasvir) has showed high virologic cure rates in treatment-naïve patients with compensated cirrhosis in the phase 3b Expedition-8 study.
Gilead Sciences announced that its GS-9674 has showed significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC) in a phase 2 trial.
Clinical stage biotechnology firm Visterra has commenced a phase 1 clinical study of VIS649 in healthy volunteers.
Glenmark Pharmaceuticals has announced plans to launch a phase 1 trial in solid tumors for its CD38xCD3 bispecific antibody GBR 1342.
Genkyotex’s NOX1/4 inhibitor GKT831 has succeeded in a phase 2 trial in primary biliary cholangitis (PBC), a type of liver disease, by meeting both primary and secondary interim efficacy endpoints.
A clinical trial collaboration has been formed to assess Bristol-Myers Squibb's (BMS) Opdivo in combination with Infinity Pharmaceuticals' IPI-549 in patients with advanced urothelial cancer.
ViiV Healthcare has reported positive results for its phase 3 BRIGHTE study of investigational fostemsavir at 48 weeks in heavily treatment-experienced (HTE) patients with HIV-1 infection.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.